Alan F List

List of Publications by Year in Descending Order

28 papers	5,195 citations	20 h-index	30 g-index
30 ext. papers	6,069 ext. citations	9.5 avg, IF	4.81 L-index

#	Paper	IF	Citations
28	Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes. *Blood Advances*, **2021**, 5, 2216-2228	7.8	10
27	Dual pyroptotic biomarkers predict erythroid response in lower risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin. *Haematologica*, **2021**,	6.6	2
26	Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia. *Clinical Cancer Research*, **2021**, 27, 6095-6105	12.9	4
25	Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia. *Clinical Cancer Research*, **2020**, 26, 54-60	12.9	11
24	The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes. *Blood*, **2019**, 133, 1039-1048	2.2	90
23	Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis. *Cancer Discovery*, **2019**, 9, 778-795	24.4	26
22	Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML. *Leukemia*, **2019**, 33, 205-216	10.7	30
21	Loss of Function of DOCK4 in Myelodysplastic Syndromes Stem Cells is Restored by Inhibitors of DOCK4 Signaling Networks. *Clinical Cancer Research*, **2019**, 25, 5638-5649	12.9	7
20	Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study. *Lancet Haematology,the*, **2018**, 5, e393-e402	14.6	26
19	Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML. *Blood*, **2017**, 130, 397-407	2.2	88
18	Pro-inflammatory proteins S100A9 and tumor necrosis factor-suppress erythropoietin elaboration in myelodysplastic syndromes. *Haematologica*, **2017**, 102, 2015-2020	6.6	16
17	SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes. *Clinical Lymphoma, Myeloma and Leukemia*, **2017**, 17, 613-620	2	3
16	A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML). *Clinical Cancer Research*, **2016**, 22, 3746-54	12.9	65
15	Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype. *Frontiers in Oncology*, **2016**, 6, 151	5.3	50
14	When clinical heterogeneity exceeds genetic heterogeneity: thinking outside the genomic box in chronic myelomonocytic leukemia. *Blood*, **2016**, 128, 2381-2387	2.2	40
13	The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. *Blood*, **2016**, 128, 2960-2975	2.2	162
12	Reduced DOCK4 expression leads to erythroid dysplasia in myelodysplastic syndromes. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, E6359-68	11.5	25

List of Publications

11	An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. *Blood*, **2015**, 125, 1857-65	2.2	118
10	The clinical management of chronic myelomonocytic leukemia. *Clinical Advances in Hematology and Oncology*, **2014**, 12, 172-8	0.6	14
9	Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure. *Clinical Lymphoma, Myeloma and Leukemia*, **2013**, 13, 711-5	2	39
8	GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. *Blood*, **2013**, 121, 5068-77	2.2	116
7	Induction of myelodysplasia by myeloid-derived suppressor cells. *Journal of Clinical Investigation*, **2013**, 123, 4595-611	15.9	187
6	Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase. *Cancer Research*, **2011**, 71, 955-63	10.1	96
5	Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. *Lancet Oncology, The*, **2009**, 10, 223-32	21.7	1961
4	Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. *Blood*, **2008**, 112, 45-52	2.2	454
3	Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. *Blood*, **2008**, 112, 3434-43	2.2	140
2	Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. *Cancer*, **2008**, 113, 1351-61	6.4	386
1	Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. *New England Journal of Medicine*, **2006**, 355, 1456-65	59.2	1029